Precise Diagnosis for Precision Lung Cancer Drug: GE Healthcare’s Clarient Diagnostics Offering FDA approved PD-L1 companion diagnostic for Merck’s Keytruda®

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

California, USA – 2 October 2015 –  Clarient Diagnostic Services, Inc. a division of GE Healthcare (NYSE:GE) announced it will be offering the FDA approved PD-L1 companion diagnostic which will help identify patients most likely to benefit from Merck’s newly-approved lung cancer drug, Keytruda.

 

http://www.genewsroom.com/press-releases/precise-diagnosis-precision-lung-cancer-drug-ge-healthcare%E2%80%99s-clarient-diagnostics